Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

NCT05174650 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: Atezolizumab
DRUG: Derazantinib

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest